Jupiter Neurosciences, Inc. Common Stock (JUNS) — Cash Flow-to-Debt Ratio
Jupiter Neurosciences, Inc. Common Stock (JUNS) has a Cash Flow-to-Debt Ratio of -0.32x as of March 2026, meaning its operating cash flow of $-2.37 Million could theoretically repay 0% of its total liabilities ($7.40 Million) in one year. See free cash flow generation of Jupiter Neurosciences, Inc. Common Stock to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jupiter Neurosciences, Inc. Common Stock Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Jupiter Neurosciences, Inc. Common Stock across 7 annual periods. Also explore Jupiter Neurosciences, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Year-by-year debt coverage analysis for Jupiter Neurosciences, Inc. Common Stock. For market capitalisation and broader financial context, see JUNS company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-5.41 Million | $7.40 Million | ▲ +62.0% |
| 2024 | -1.93x | $-3.91 Million | $2.03 Million | ▼ -2283.0% |
| 2023 | -0.08x | $-480.95K | $5.95 Million | ▲ +52.2% |
| 2022 | -0.17x | $-1.25 Million | $7.38 Million | ▲ +43.0% |
| 2021 | -0.30x | $-1.74 Million | $5.85 Million | ▼ -396.4% |
| 2020 | -0.06x | $-254.78K | $4.26 Million | ▼ -110.1% |
| 2019 | -0.03x | $-142.95K | $5.02 Million | — |